Immune reconstitution inflammatory syndrome: The trouble with immunity when you had none

Nature Reviews Microbiology

Volumn 10, Issue 2, 2012, Pages 150-156

  Barber, Daniel L ^a   Andrade, Bruno B ^a   Sereti, Irini ^a   Sher, Alan ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CORTICOSTEROID; NATALIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; DRUG WITHDRAWAL; GRAFT RECIPIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INNATE IMMUNITY; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; VIRUS INHIBITION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE TOLERANCE; IMMUNITY, INNATE; LYMPHOPENIA; MICE; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; RISK FACTORS;

EID: 84855869282     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro2712     Document Type: Review

References (71)

1. Zolopa, A. et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 4, e5575(2009).
2. Abdool Karim, S. S. et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med. 362, 697-706(2010).
3. Castelnuovo, B. et al. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban african cohort. Clin. Infect. Dis. 49, 965-972(2009).
4. Abdool Karim, S. S. et al. Integration of antiretroviral therapy with tuberculosis treatment. N. Engl. J. Med. 365, 1492-1501(2011).
5. Hoyo-Ulloa, I. et al. Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and morbidity in HIV-infected patients in Mexico. Int. J. Infect. Dis. 15, e408-e414(2011).
6. Blanc, F.-X. et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med. 365, 1471-1481(2011).
7. Havlir, D. V. et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med. 365, 1482-1491(2011).
8. French, M. A. et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 1, 107-115(2000).
9. Ratnam, I., Chiu, C., Kandala, N.-B. & Easterbrook, P. J. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin. Infect. Dis. 42, 418-427(2006). (Pubitemid 43122323)
10. Murdoch, D. M., Venter, W. D. F., Feldman, C. & Van Rie, A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 22, 601-610(2008). (Pubitemid 351640593)
11. Grant, P. M. et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS ONE 5, e11416(2010).
12. Breton, G. et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS 20, 119-121(2006). (Pubitemid 41818123)
13. Nolan, R. C., Chidlow, G. & French, M. A. Parvovirus B19 encephalitis presenting as immune restoration disease after highly active antiretroviral therapy for human immunodeficiency virus infection. Clin. Infect. Dis. 36, 1191-1194(2003). (Pubitemid 36549643)
14. Connick, E., Kane, M. A., White, I. E., Ryder, J. & Campbell, T. B. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin. Infect. Dis. 39, 1852-1855(2004). (Pubitemid 39657269)
15. Mueller, M. et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect. Dis. 10, 251-261(2010).
16. Manabe, Y. C., Campbell, J. D., Sydnor, E. & Moore, R. D. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J. Acquir. Immune Defic. Syndr. 46, 456-462(2007). (Pubitemid 350098697)
17. Meintjes, G. et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect. Dis. 8, 516-523(2008). (Pubitemid 352005824)
18. Bourgarit, A. et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 20, F1-F7(2006).
19. Bourgarit, A. et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative γδ T cells. J. Immunol. 183, 3915-3923(2009).
20. Meintjes, G. et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am. J. Respir. Crit. Care Med. 178, 1083-1089(2008).
21. Roths, J. B., Marshall, J. D., Allen, R. D., Carlson, G. A. & Sidman, C. L. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. Natural history and pathobiology. Am. J. Pathol. 136, 1173-1186(1990). (Pubitemid 20188504)
22. + T cells into severe combined immunodeficiency mice. J. Clin. Invest. 90, 673-678(1992).
23. Roths, J. B. & Sidman, C. L. Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice. Infect. Immun. 61, 1641-1649(1993). (Pubitemid 23145856)
24. Gigliotti, F., Xu, H. & Wright, T. Contribution of T cell subsets to the pathophysiology of Pneumocystisrelated immunorestitution disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 291, L1256-L1266(2006). (Pubitemid 44904532)
25. Atochina-Vasserman, E. N. et al. Immune reconstitution during pneumocystis lung infection: disruption of surfactant component expression and function by S-nitrosylation. J. Immunol. 182, 2277-2287(2009).
26. French, M. A., Mallal, S. A. & Dawkins, R. L. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 6, 1293-1297(1992).
27. Barber, D. L. et al. Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 116, 3485-3493(2010).
28. Elliott, J. H. et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J. Infect. Dis. 200, 1736-1745(2009).
29. + patients developing immune reconstitution inflammatory syndrome. Blood 116, 3818-3827(2010).
30. Tan, D. B. A. et al. TLR2-induced cytokine responses may characterize HIV-infected patients experiencing mycobacterial immune restoration disease. AIDS 25, 1455-1460(2011).
31. Krupica, T., Fry, T. J. & Mackall, C. L. Autoimmunity during lymphopenia: a two-hit model. Clin. Immunol. 120, 121-128(2006). (Pubitemid 44088681)
32. Sprent, J. & Surh, C. D. Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Nature Immunol. 131, 478-484(2011).
33. + T cell anergy and promotes tumor rejection. J. Immunol. 177, 4521-4529(2006). (Pubitemid 44469783)
34. King, C., Ilic, A., Koelsch, K. & Sarvetnick, N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117, 265-277(2004). (Pubitemid 38496245)
35. Tan, J. T. et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl Acad. Sci. USA 98, 8732-8737(2001). (Pubitemid 32678096)
36. Schluns, K. S., Kieper, W. C., Jameson, S. C. & Lefrançois, L. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nature Immunol. 1, 426-432(2000).
37. Kieper, W. C. et al. Recent immune status determines the source of antigens that drive homeostatic T cell expansion. J. Immunol. 174, 3158-3163(2005). (Pubitemid 40354015)
38. Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345, 1098-1104(2001).
39. Wallis, R. S., van Vuuren, C. & Potgieter, S. Adalimumab treatment of life-threatening tuberculosis. Clin. Infect. Dis. 48, 1429-1432(2009).
40. Yoon, Y. K. et al. Paradoxical response during antituberculous therapy in a patient discontinuing infliximab: a case report. J. Med. Case Rep. 3, 6673(2009).
41. Belknap, R., Reves, R. & Burman, W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int. J. Tuberc. Lung Dis. 9, 1057-1058(2005). (Pubitemid 41549197)
42. Arend, S. M., Leyten, E. M. S., Franken, W. P. J., Huisman, E. M. & van Dissel, J. T. A patient with de novo tuberculosis during anti-tumor necrosis factor-α therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin. Infect. Dis. 45, 1470-1475(2007). (Pubitemid 351411877)
43. Szerszen, A., Gupta, S., Seminara, D., Jarrett, M. & Goldstein, M. Peritoneal tuberculosis complicated by immune reconstitution inflammatory syndrome in a patient treated with infliximab?: a case for adjuvant immunosuppressive therapy. J. Clin. Rheumatol. 15, 417-418(2009).
44. Garcia Vidal, C. et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin. Infect. Dis. 40, 756-759(2005).
45. Rivoisy, C., Amrouche, L., Carcelain, G., Sereni, D. & Bourgarit, A. Paradoxical exacerbation of tuberculosis after TNFα antagonist discontinuation: beware of immune reconstitution inflammatory syndrome. Joint Bone Spine 78, 312-315(2011).
46. Khatri, B. O. et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72, 402-409(2009).
47. Clifford, D. B. et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 9, 438-446(2010).
48. Johnson, T. & Nath, A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr. Opin. Neurol. 24, 284-290(2011).
49. Van Assche, G. et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362-368(2005). (Pubitemid 41132340)
50. Lindå, H. et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med. 361, 1081-1087(2009).
51. Ryschkewitsch, C. F. et al. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 68, 384-391(2010).
52. Miravalle, A., Jensen, R. & Kinkel, R. P. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch. Neurol. 68, 186-191(2011).
53. Sun, H. Y. & Singh, N. Opportunistic infectionassociated immune reconstitution syndrome in transplant recipients. Clin. Infect. Dis. 53, 168-176(2011).
54. Legris, T. et al. Immune reconstitution inflammatory syndrome mimicking relapsing cryptococcal meningitis in a renal transplant recipient. Transpl. Infect. Dis. 13, 303-308(2011).
55. Singh, N. et al. An immune reconstitution syndromelike illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin. Infect. Dis. 40, 1756-1761(2005). (Pubitemid 40799944)
56. Crespo, G. et al. Immune reconstitution syndrome after voriconazole treatment for cryptococcal meningitis in a liver transplant recipient. Liver Transpl. 14, 1671-1674(2008).
57. Lanternier, F. et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am. J. Transplant. 7, 2826-2828(2007). (Pubitemid 350045770)
58. Singh, N. Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses. Eur. J. Clin. Microbiol. Infect. Dis. 27, 403-408(2008). (Pubitemid 351713067)
59. Boulware, D. R. et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 7, e1000384(2010).
60. Boulware, D. R. et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J. Infect. Dis. 202, 962-970(2010).
61. + T cells induce innate responses independently of pathogen. Nature Med. 16, 558-564(2010).
62. Barber, D. L., Mayer-Barber, K. D., Feng, C. G., Sharpe, A. H. & Sher, A. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J. Immunol. 186, 1598-1607(2011).
63. Tadokera, R. et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur. Respir. J. 37, 1248-1259(2011).
64. Boulware, D. R. et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J. Infect. Dis. 203, 1637-1646(2011).
65. Oliver, B. G. et al. Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. J. Infect. Dis. 202, 1728-1737(2010).
66. Lawn, S. D., Wainwright, H. & Orrell, C. Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: the role of macrophages. AIDS 23, 143-145(2009).
67. Lawn, S. D., Myer, L., Bekker, L.-G. & Wood, R. Tuberculosis- associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 21, 335-341(2007). (Pubitemid 46175045)
68. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescencents, 10 Jan 2011. AIDSinfo [online] http://www.aidsinfo.nih.gov/Contentfiles/AdultandAdolescentGL. pdf (2011).
69. Török, M. E. et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin. Infect. Dis. 52, 1374-1383(2011).
70. Meintjes, G. et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 24, 2381-2390(2010).
71. French, M. A. Immune reconstitution inflammatory syndrome: a reappraisal. Clin. Infect. Dis. 48, 101-107(2009).